Why is RWE, within the realm of data, gaining increasing importance not just from a payer perspective but also from a regulatory perspective?
Well, the FDAs new strategic framework to advance use of RWE to support development of drugs and biologics has recently come out. This reinforces the fact that there is an ever growing interest to not only generate real world evidence but also demonstrate value to relevant stakeholders involved in the patient access decision making process. New age healthcare apps and digital therapeutics are also gaining a lot of traction, and real world evidence is critical in measuring the impact of these interventions on health outcomes.
This webinar will showcase how RWE and data analytics can be leveraged for evidence generation and value demonstration. Leading industry SMEs and speakers will provide their unique perspectives on the topic and discuss how life sciences organization are securely and efficiently driving their real world evidence initiatives.
Topics:
- Generating and Harnessing Real World Evidence in the Era of Big Data
- Immuno-oncology, Survival Modeling and Nice Assessment: Get Ahead of the Curve
- How to collect RWE to show an App Increases Patient Engagement & Improves Outcomes
Click here for additional information and registration details.